New Delhi: The drug regulators of seven states have alleged that 27 medicines sold by 18 major drug companies in India are of “substandard” quality.
The grounds cited for “substandard” quality drugs include false labelling, wrong quantity of ingredients, discolouration, moisture formation, failing dissolution test and failing disintegration test, reports Indian Express.
The tests on the 27 medicines were done by drug regulators of Maharashtra, Karnataka, West Bengal, Goa, Gujarat, Kerala and Andhra Pradesh.
The companies whose drugs were found to be of “substandard” quality include Abbott India, GSK India, Sun Pharma, Cipla, Glenmark Pharma, Alkem Laboratories, Cadila Healthcare, Cipla, Emcure Pharmaceuticals, Hetero Labs, Morepen, Macleods Pharma, Wockhardt Pharma, Zydus, Alembic Pharma, Ipca Labs, Sanofi-Synthelabo and Torrent Pharma.
Some of the key brands which were alleged to be substandard are: antipsychotic drug Stemetil; antibiotic drug Pentids; anti-bacterial medicine Althrocin; migraine medication Vasograin; cough syrup Ascoril; worm infection drug Zentel; arthritis medication Hydroxychloroquine (HCQS); anti-inflammatory medication Myoril; and hypertension drug Dilzem.